NASDAQ:JUNO Juno Therapeutics (JUNO) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$86.96▼$86.9650-Day Range$86.96▼$86.9652-Week Range$19.62▼$87.01Volume2 shsAverage Volume5.48 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media About Juno Therapeutics (NASDAQ:JUNO) StockJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.Read More Receive JUNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JUNO Stock News HeadlinesMay 18, 2023 | bizjournals.comCancer-fighting biotech startup Indapta lands $30M with assist from FDAMay 13, 2023 | marketwatch.com2030, Multiple Myeloma Therapeutics Market: Trend & OutlookJune 10, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See The True Value of Any StockGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 10, 2023 | finanznachrichten.deChinook Therapeutics, Inc.: Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesMay 10, 2023 | marketwatch.com2023-2031 "CAR T-Cell Therapy Market" Development: Key Players Analysis and Innovative Growth OpportunitiesMay 5, 2023 | marketwatch.com2023-2030 Multiple Myeloma Therapeutics Market Size (Growth and Outlook) includes Sales Channel and Regional Analysis | with [101 Pages]May 5, 2023 | marketwatch.comCAR T-Cell Therapy Market Share and Forecast till 2030May 3, 2023 | marketwatch.comGlobal Indolent Lymphoma Treatment Market by Size, Trend & New Technology till 2023-2030June 10, 2023 | Behind the Markets (Ad)⚡ 2,467% Return on Israeli Laser Company?This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.April 29, 2023 | businessinsider.comJuno review: Digital high-yield checking account with cash back rewardsApril 29, 2023 | marketwatch.comMultiple Myeloma Therapeutics Market Top Key Players by 2030April 28, 2023 | marketwatch.comCAR T-Cell Therapy Market Research Analysis 2023-2031April 24, 2023 | marketwatch.comNeuroblastoma Treatment Market Insights and Segmentation Until 2031April 19, 2023 | marketwatch.comCAR T-Cell Therapy Market 2023 Global Report Insights 2029April 17, 2023 | bizjournals.comFormer Eliem CEO Bob Azelby joins board of Chinook TherapeuticsApril 12, 2023 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Announces Leadership ChangesApril 10, 2023 | finance.yahoo.comTune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General CounselApril 3, 2023 | finance.yahoo.comAnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business OfficerMarch 30, 2023 | marketwatch.comCAR-T Therapy Market Analysis by Global Report Research, 2029March 27, 2023 | marketwatch.comMultiple Myeloma Therapeutics Market | Newsest ResearchMarch 26, 2023 | marketwatch.comGlobal Multiple Myeloma Therapeutics Market In-Depth Analysis, Business Forecast, and Dynamics 2023 – 2030 By VMReportsMarch 17, 2023 | marketwatch.com2023 to 2028 CAR T-Cell Therapy Market Forecasting Future Growth OutlookMarch 14, 2023 | marketwatch.com2029 Forecast CAR-T Therapy Market 2023 by Growth Rate, Sparked Innovation with Top PlayersMarch 11, 2023 | marketwatch.comImmune Repertoire Sequencing Market 2023-2028 New Review by Competitor Analysis and Recent DevelopmentMarch 6, 2023 | marketwatch.comCAR-T Therapy Market is Growing Globally Forecast 2023-2028March 2, 2023 | marketwatch.com2023-2029 Acute Lymphocytic Leukemia Therapeutics Market Size and Risks Factors Analysis | Survey Report by Absolute ReportsMarch 1, 2023 | marketwatch.comGlobal Hairy Cell Leukemia Therapeutics Market Upcoming Trends, Opportunities by Types and Application to 2030 By VMReportsSee More Headlines JUNO Company Calendar Last Earnings11/01/2017Today6/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:JUNO CUSIPN/A CIK1594864 Webwww.junotherapeutics.com Phone+1-206-5821600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Key ExecutivesHoward H. Pien (Age 59)Independent Chairman of the Board Hans Edgar Bishop (Age 53)President, Chief Executive Officer, Director Sunil Agarwal M.D. (Age 47)President of Research & Development Steven D. Harr M.D. (Age 46)Chief Financial Officer, Head of Corporate Development Hyam I. Levitsky M.D (Age 54)Executive vice president - Research, chief scientific officer Robert W. Azelby (Age 49)Executive Vice President, Chief Commercial Officer Ann Lee Ph.D.Executive Vice President - Technical OperationsPatrick Y. Yang (Age 69)Executive Vice President Cynthia ElkinsChief Information OfficerBernard J. Cassidy (Age 62)General Counsel, Secretary More Executives JUNO Stock - Frequently Asked Questions How were Juno Therapeutics' earnings last quarter? Juno Therapeutics Inc (NASDAQ:JUNO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. The firm's revenue was up 115.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.57) earnings per share. What other stocks do shareholders of Juno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI). When did Juno Therapeutics IPO? (JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager. What is Juno Therapeutics' stock symbol? Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO." What is Juno Therapeutics' stock price today? One share of JUNO stock can currently be purchased for approximately $86.96. How can I contact Juno Therapeutics? Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The official website for the company is www.junotherapeutics.com. The biopharmaceutical company can be reached via phone at +1-206-5821600. This page (NASDAQ:JUNO) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juno Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.